[go: up one dir, main page]

MA38498A1 - Protéines de liaison anti-lag-3 - Google Patents

Protéines de liaison anti-lag-3

Info

Publication number
MA38498A1
MA38498A1 MA38498A MA38498A MA38498A1 MA 38498 A1 MA38498 A1 MA 38498A1 MA 38498 A MA38498 A MA 38498A MA 38498 A MA38498 A MA 38498A MA 38498 A1 MA38498 A1 MA 38498A1
Authority
MA
Morocco
Prior art keywords
lag
binding proteins
antigen
lymphocyte
bind
Prior art date
Application number
MA38498A
Other languages
English (en)
Other versions
MA38498B1 (fr
Inventor
Paul Andrew Hamblin
Alan Peter Lewis
Thomas Matthew Webb
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA38498A1 publication Critical patent/MA38498A1/fr
Publication of MA38498B1 publication Critical patent/MA38498B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des protéines de liaison à un antigène qui se lient au gène 3 d'activation des lymphocytes (lag-3), et plus particulièrement des protéines de liaison à un antigène qui provoquent une déplétion de lymphocytes t activés lag-3+.
MA38498A 2013-03-15 2014-03-13 Protéines de liaison anti-lag-3 MA38498B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789325P 2013-03-15 2013-03-15
PCT/EP2014/054967 WO2014140180A1 (fr) 2013-03-15 2014-03-13 Protéines de liaison anti-lag-3

Publications (2)

Publication Number Publication Date
MA38498A1 true MA38498A1 (fr) 2017-07-31
MA38498B1 MA38498B1 (fr) 2018-11-30

Family

ID=50272641

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38498A MA38498B1 (fr) 2013-03-15 2014-03-13 Protéines de liaison anti-lag-3

Country Status (36)

Country Link
US (6) US10280221B2 (fr)
EP (2) EP2970464B1 (fr)
JP (3) JP6224739B2 (fr)
KR (1) KR101763352B1 (fr)
CN (1) CN105209494B (fr)
AR (1) AR095432A1 (fr)
AU (1) AU2014230741B2 (fr)
CA (1) CA2902831C (fr)
CL (1) CL2015002517A1 (fr)
CR (1) CR20150492A (fr)
CY (1) CY1123220T1 (fr)
DK (1) DK2970464T3 (fr)
DO (1) DOP2015000243A (fr)
EA (1) EA037554B1 (fr)
ES (1) ES2808654T3 (fr)
HK (1) HK1219966A1 (fr)
HR (1) HRP20201113T1 (fr)
HU (1) HUE049957T2 (fr)
IL (1) IL240838B (fr)
LT (1) LT2970464T (fr)
MA (1) MA38498B1 (fr)
ME (1) ME03796B (fr)
MX (1) MX351349B (fr)
NZ (1) NZ711355A (fr)
PE (1) PE20151530A1 (fr)
PH (1) PH12015502039B1 (fr)
PL (1) PL2970464T3 (fr)
PT (1) PT2970464T (fr)
RS (1) RS60538B1 (fr)
SG (1) SG11201506807RA (fr)
SI (1) SI2970464T1 (fr)
SM (1) SMT202000392T1 (fr)
TW (1) TWI658051B (fr)
UA (1) UA118750C2 (fr)
UY (1) UY35415A (fr)
WO (1) WO2014140180A1 (fr)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031371T2 (en) 2010-08-23 2017-07-28 Univ Texas Anti-ox40 antibodies and methods of using the same
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
PT2970464T (pt) 2013-03-15 2020-08-05 Glaxosmithkline Ip Dev Ltd Proteínas de ligação anti-lag-3
PT3508502T (pt) 2013-09-20 2023-06-22 Bristol Myers Squibb Co Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
SI3116909T1 (sl) 2014-03-14 2020-03-31 Novartis Ag Molekule protiteles na LAG-3 in njih uporaba
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CA3012602A1 (fr) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Materiaux peritumoraux et intratumoraux pour traitement anticancereux
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
ES2803655T3 (es) 2015-05-29 2021-01-28 Agenus Inc Aticuerpos anti-ctla-4 y métodos de uso de los mismos
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EP3744340A3 (fr) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions et procédés pour le traitement du cancer
DK3981792T3 (da) 2015-07-30 2024-09-02 Macrogenics Inc PD-1-bindende molekyler og fremgangsmåder til anvendelse deraf
JP7074341B2 (ja) 2015-09-02 2022-05-24 イムテップ エス．アー．エス． 抗ｌａｇ－３抗体
CR20180161A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Anticuerpos biespecíficos para pd1 y tim3
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
JP6945456B2 (ja) * 2015-11-13 2021-10-06 マクロジェニクス，インコーポレーテッド Ｌａｇ‐３結合分子及びその使用方法
WO2017087901A2 (fr) * 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anticorps anti-lag3, compositions comprenant des anticorps anti-lag3 et méthodes de production et d'utilisation d'anticorps anti-lag3
WO2017106061A1 (fr) 2015-12-14 2017-06-22 Macrogenics, Inc. Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
CA3008244A1 (fr) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anticorps anti-lag3 et fragments de fixation a l'antigene
SG10201601719RA (en) * 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
BR112018072986A2 (pt) * 2016-05-18 2019-03-06 Boehringer Ingelheim International Gmbh anticorpos anti-pd-1 e anti-lag3 para tratamento de câncer
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
AU2017281157B2 (en) 2016-06-20 2024-07-25 F-Star Therapeutics Limited LAG -3 binding members
AU2017283181B2 (en) 2016-06-20 2024-08-15 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
BR112018076281A2 (pt) 2016-06-20 2019-03-26 Kymab Limited imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
RU2757813C2 (ru) * 2016-06-23 2021-10-21 Цзянсу Хэнжуй Медицин Ко., Лтд. Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EA039718B1 (ru) * 2016-07-21 2022-03-03 Регенерон Фармасьютикалз, Инк. Антитела к lag3 и их применения
CN110088132B (zh) 2016-08-17 2020-10-27 康姆普根有限公司 抗tigit抗体，抗pvrig抗体及其组合
CN109689870B (zh) * 2016-09-08 2022-11-29 第一三共株式会社 用于治疗自身免疫疾病的抗体
TWI773694B (zh) 2016-10-11 2022-08-11 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
IL265844B2 (en) 2016-10-13 2024-03-01 Symphogen As Anti-lag-3 antibodies and compositions
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
MX2019009565A (es) 2017-02-10 2020-02-24 Regeneron Pharma Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet.
KR102236259B1 (ko) * 2017-02-22 2021-04-06 아이-맵 바이오파마 유에스 리미티드 항-lag-3 항체 및 그것의 사용
AU2018247765B2 (en) 2017-04-03 2023-11-23 F. Hoffmann-La Roche Ag Immunoconjugates of an Anti-PD-1 antibody with a mutant IL-2 or with IL-15
CN114984209A (zh) 2017-04-05 2022-09-02 西福根有限公司 靶向pd-1、tim-3及lag-3的组合疗法
PT3606955T (pt) 2017-04-05 2025-01-09 Hoffmann La Roche Anticorpos biespecíficos que se ligam especificamente a pd1 e a lag3
DK3606954T3 (en) 2017-04-05 2022-09-26 Hoffmann La Roche Anti-LAG3-antistoffer
EP3615572A1 (fr) * 2017-04-27 2020-03-04 Tesaro Inc. Agents anticorps dirigés contre la protéine codée par le gène d'activation des lymphocytes 3 (lag-3) et utilisations associées
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
DK3631454T3 (da) 2017-05-30 2023-12-04 Bristol Myers Squibb Co Behandling af lag-3 positive tumorer
WO2018222722A2 (fr) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprenant un anticorps anti-lag-3 ou un anticorps anti-lag-3 et un anticorps anti-pd-1 ou anti-pd-l1
KR20200010500A (ko) 2017-05-30 2020-01-30 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체, pd-1 경로 억제제, 및 면역요법제의 조합을 포함하는 조성물
WO2018229715A1 (fr) 2017-06-16 2018-12-20 Novartis Ag Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
CR20190593A (es) 2017-06-22 2020-05-10 Novartis Ag Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
WO2018235056A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
CA3061874A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Utilisation d'anticorps de liaison il-1s dans le traitement du cancer
MX2019015738A (es) 2017-06-27 2020-02-20 Novartis Ag Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
JP6896989B2 (ja) * 2017-07-13 2021-06-30 ナンジン リーズ バイオラブズ カンパニー リミテッド 抗体結合ｌａｇ−３及びその使用
EP3655023A1 (fr) 2017-07-20 2020-05-27 Novartis AG Régimes posologiques pour des anticorps anti-lag3 et leurs utilisations
KR102758037B1 (ko) 2017-08-18 2025-01-22 코테라 바이오사이언스 인코포레이티드 Tg02의 다형성 형태
CN111050792B (zh) * 2017-08-30 2024-05-31 凡恩世制药(北京)有限公司 抗lag-3抗体及其用途
WO2019055579A1 (fr) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Régime de traitement pour des cancers qui sont insensibles aux inhibiteurs de bcl-2 à l'aide de l'inhibiteur de mcl-1 alvocidib
WO2019070013A1 (fr) * 2017-10-05 2019-04-11 第一三共株式会社 Composition pour déplétion de lymphocytes t cytotoxiques
WO2019081983A1 (fr) 2017-10-25 2019-05-02 Novartis Ag Anticorps ciblant cd32b et leurs procédés d'utilisation
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
CN111727373A (zh) 2017-11-30 2020-09-29 诺华股份有限公司 靶向bcma的嵌合抗原受体及其用途
US11548948B2 (en) 2017-12-19 2023-01-10 F-Star Therapeutics Limited FC binding fragments comprising a PD-L1 antigen-binding site
KR20200104314A (ko) 2017-12-22 2020-09-03 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Lag-3 항체 약학 조성물 및 이의 용도
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN112218651A (zh) 2018-01-08 2021-01-12 诺华公司 用于与嵌合抗原受体疗法组合的免疫增强rna
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
CN111655730A (zh) 2018-01-31 2020-09-11 豪夫迈·罗氏有限公司 包含与lag3结合的抗原结合位点的双特异性抗体
EP3752203A1 (fr) 2018-02-13 2020-12-23 Novartis AG Thérapie par récepteur antigénique chimérique en combinaison avec il-15 r et il15
JP7438180B2 (ja) * 2018-03-20 2024-02-26 ウーシー バイオロジクス アイルランド リミテッド 新規抗ｌａｇ－３抗体ポリペプチド
EP3778639A4 (fr) * 2018-04-02 2021-06-09 Mab-Venture Biopharm Co., Ltd. Anticorps se liant au gène d'activation lymphocytaire 3 (lag-3) et son utilisation
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
CN110615840A (zh) * 2018-06-19 2019-12-27 信达生物制药(苏州)有限公司 全人源的抗lag-3抗体及其应用
US11192877B2 (en) 2018-07-10 2021-12-07 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
JP7397055B2 (ja) 2018-07-12 2023-12-12 エフ－スター セラピューティクス リミテッド Ｃｄ１３７及びｏｘ４０に結合する抗体分子
WO2020021465A1 (fr) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Procédé de traitement de tumeurs neuroendocrines
JP2021532143A (ja) 2018-07-26 2021-11-25 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 癌の処置のためのｌａｇ−３併用療法
HRP20241325T1 (hr) 2018-10-19 2024-12-20 Bristol-Myers Squibb Company Kombinirana terapija za melanom
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
CN113490499A (zh) 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
CA3119582A1 (fr) 2018-12-21 2020-06-25 Novartis Ag Utilisation d'anticorps de liaison de il-1.beta.
EP3897613A1 (fr) 2018-12-21 2021-10-27 Novartis AG Utilisation d'anticorps de liaison à il-1bêta
WO2020128637A1 (fr) 2018-12-21 2020-06-25 Novartis Ag UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H
MX2021007271A (es) 2018-12-21 2021-07-15 Onxeo Nuevas moleculas de acido nucleico conjugado y sus usos.
EP3898675A1 (fr) 2018-12-21 2021-10-27 Novartis AG Utilisation d'anticorps de liaison à il-1 bêta dans le traitement ou la prévention du syndrome myélodysplasique
WO2020167990A1 (fr) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprenant des inhibiteurs de protéine kinase hétérocycliques
EA202192019A1 (ru) 2019-02-15 2021-11-02 Новартис Аг Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
EP3935581A4 (fr) 2019-03-04 2022-11-30 Iocurrents, Inc. Compression et communication de données à l'aide d'un apprentissage automatique
WO2020191326A1 (fr) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Traitement de la leucémie myéloïde aiguë (aml) après échec du vénétoclax
EP3941463A1 (fr) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant
WO2020198435A1 (fr) 2019-03-26 2020-10-01 The Regents Of The University Of Michigan Agents de dégradation, à petites molécules, de stat3
US20220134727A1 (en) 2019-03-29 2022-05-05 Nitto Denko Corporation Method for manufacturing laminate, method for manufacturing coated article, method for manufacturing bonded structure, thermal transfer sheet, and laminate
US20220185831A1 (en) 2019-03-29 2022-06-16 The Regents Of The University Of Michigan Stat3 protein degraders
MX2021013815A (es) 2019-05-13 2021-12-14 Regeneron Pharma Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer.
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
EP3976832A1 (fr) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Procédés d'identification d'un sujet approprié pour une thérapie d'immuno-oncologie (i-o)
CN115340606B (zh) * 2019-05-31 2023-12-19 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
WO2020250940A1 (fr) * 2019-06-11 2020-12-17 小野薬品工業株式会社 Agent d'immunosuppression
EP3983084A1 (fr) 2019-06-12 2022-04-20 Vanderbilt University Inhibiteurs de transport d'acides aminés et utilisations associées
AU2020291936A1 (en) 2019-06-12 2022-02-03 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
PH12021553233A1 (en) 2019-07-16 2022-09-19 Univ Michigan Regents Imidazopyrimidines as eed inhibitors and the use thereof
WO2021024020A1 (fr) 2019-08-06 2021-02-11 Astellas Pharma Inc. Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer
WO2021041664A1 (fr) 2019-08-27 2021-03-04 The Regents Of The University Of Michigan Inhibiteurs de ligase e3 cereblon
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
US20220380368A1 (en) 2019-09-19 2022-12-01 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
BR112022004316A2 (pt) 2019-09-22 2022-06-21 Bristol Myers Squibb Co Caracterização espacial quantitativa para terapia de antagonista lag-3
CA3157665A1 (fr) 2019-10-21 2021-04-29 Novartis Ag Inhibiteurs de tim-3 et leurs utilisations
BR112022007376A2 (pt) 2019-10-21 2022-07-05 Novartis Ag Terapias de combinação com venetoclax e inibidores de tim-3
WO2021092221A1 (fr) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle
WO2021092220A1 (fr) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle
AU2020380384A1 (en) 2019-11-08 2022-05-26 Bristol-Myers Squibb Company LAG-3 antagonist therapy for melanoma
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
EP4090335A1 (fr) 2020-01-17 2022-11-23 Novartis AG Polythérapies comprenant un inhibiteur tim-3 et un agent d'hypométhylation à utiliser dans le traitement du syndrome myélodysplasique ou de la leucémie myélomonocytaire chronique
CN115362167A (zh) 2020-02-06 2022-11-18 百时美施贵宝公司 Il-10及其用途
WO2021195481A1 (fr) 2020-03-26 2021-09-30 The Regents Of The University Of Michigan Agents de dégradation de protéine stat à petites molécules
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
IL298993A (en) 2020-07-07 2023-02-01 BioNTech SE Therapeutic rna for hpv-positive cancer
US20230257365A1 (en) 2020-07-10 2023-08-17 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
WO2022011205A1 (fr) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Agents de dégradation de protéine de récepteur des androgènes
EP4188549A1 (fr) 2020-08-03 2023-06-07 Novartis AG Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione substitués par hétéroaryle et leurs utilisations
CA3193421A1 (fr) 2020-08-28 2022-03-03 Bristol-Myers Squibb Company Therapie par antagoniste de lag-3 pour le carcinome hepatocellulaire
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204453A1 (fr) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Signature de localisation cellulaire et immunothérapie
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022120179A1 (fr) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Signatures géniques multi-tumorales et leurs utilisations
KR20220082558A (ko) 2020-12-10 2022-06-17 재단법인 의약바이오컨버젼스연구단 면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Arn thérapeutique pour le traitement du cancer
WO2022135666A1 (fr) 2020-12-21 2022-06-30 BioNTech SE Programme de traitement faisant intervenir des protéines cytokines
CA3196999A1 (fr) 2020-12-28 2022-07-07 Masano HUANG Methodes de traitement des tumeurs
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2022187423A1 (fr) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Ligands de céréblon
WO2022187419A1 (fr) 2021-03-03 2022-09-09 The Regents Of The University Of Michigan Agents de dégradation à petites molécules du récepteur des androgènes
CN117858719A (zh) 2021-03-29 2024-04-09 朱诺治疗学股份有限公司 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
KR20230170039A (ko) 2021-04-13 2023-12-18 뉴베일런트, 아이엔씨. Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
EP4337694A1 (fr) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Agents inhibiteurs de lag3 et gal3, peptides xbp1, cs1 et cd138, et leurs méthodes d'utilisation
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
MX2024000674A (es) 2021-07-13 2024-02-07 BioNTech SE Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
AU2022375806A1 (en) 2021-10-29 2023-12-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
CA3240558A1 (fr) 2021-12-16 2023-06-22 Valerio Therapeutics Nouvelles molecules d'acide nucleique conjuguees et leurs utilisations
AU2023213937A1 (en) 2022-01-26 2024-07-18 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
KR20240153583A (ko) 2022-02-25 2024-10-23 브리스톨-마이어스 스큅 컴퍼니 결장직장암종에 대한 병용 요법
WO2023168404A1 (fr) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Méthodes de traitement d'une tumeur
WO2023170606A1 (fr) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Utilisation d'anticorps anti-claudine-1 pour augmenter la disponibilité des lymphocytes t
IL314346A (en) 2022-03-15 2024-09-01 Compugen Ltd Antibodies antagonistic to IL-18BP and their use in monotherapy and combination therapy in cancer treatment
CN118871451A (zh) 2022-03-18 2024-10-29 百时美施贵宝公司 分离多肽的方法
WO2023214325A1 (fr) 2022-05-05 2023-11-09 Novartis Ag Dérivés de pyrazolopyrimidine et leurs utilisations en tant qu'inhibiteurs de tet2
WO2023235847A1 (fr) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Compositions d'anticorps et leurs procédés d'utilisation
WO2023239197A1 (fr) 2022-06-09 2023-12-14 주식회사 자이메디 Nouveau peptide de fragment crs ayant une activité d'immunopotentialisation et utilisation associée
TW202440157A (zh) 2022-12-01 2024-10-16 英商梅迪繆思有限公司 用於治療癌症的組合療法
WO2024126457A1 (fr) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Polythérapie impliquant des agents de liaison bispécifiques se liant à cldn18.2 et cd3 et des inhibiteurs de point de contrôle immunitaire
WO2024137776A1 (fr) 2022-12-21 2024-06-27 Bristol-Myers Squibb Company Polythérapie contre le cancer du poumon
WO2024173876A1 (fr) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
WO2024192033A1 (fr) 2023-03-13 2024-09-19 Regeneron Pharmaceuticals, Inc. Combinaison d'inhibiteurs de pd-1 et d'inhibiteurs de lag-3 pour une efficacité améliorée dans le traitement d'un mélanome
WO2024196952A1 (fr) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Évaluation de sous-type de tumeur pour une thérapie anticancéreuse
US20240425607A1 (en) 2023-06-26 2024-12-26 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2025038763A1 (fr) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Procédé de chromatographie en flux continu d'hydroxyapatite céramique

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
WO1991014438A1 (fr) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
DE69624824T2 (de) 1995-07-21 2003-09-11 Applied Research Systems Ars Holding N.V., Curacao Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein
JP2000509015A (ja) 1996-03-27 2000-07-18 シーアールシー フォー バイオファーマシューティカル リサーチ ピーティーワイ．リミテッド Ｔ細胞及びｂ細胞リンパ腫及び白血病の治療のためのｃｄ４８に対する抗体の使用
WO1997043316A1 (fr) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Molecules physiologiquement actives a demi-vies prolongees et methode d'utilisation de ces dernieres
WO1999015553A2 (fr) 1997-09-23 1999-04-01 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Polypeptide costimulant de lymphocytes t, anticorps monoclonaux, leur production et leur utilisation
JP2002505086A (ja) 1998-02-25 2002-02-19 レキシジェン ファーマシューティカルズ コーポレイション 抗体ベースの融合タンパク質の循環半減期の増強
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
CA2341029A1 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
CA2369292C (fr) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Methode de modulation de l'activite de molecules immunitaires fonctionnelles
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1572936A2 (fr) 2002-03-05 2005-09-14 Eli Lilly And Company Proteines hybrides g-csf heterologues
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1596871A4 (fr) 2003-02-28 2006-08-23 Drew M Pardoll Regulation par lymphocytes t
PL1639011T3 (pl) 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
WO2005040229A2 (fr) 2003-10-24 2005-05-06 Avidia, Inc. Multimeres et monomeres comprenant des domaines de recepteur de lipoproteines de basse densite de classe a et egf
SI1729795T1 (sl) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
US8318905B2 (en) 2004-04-23 2012-11-27 Richard Kroczek Antibodies for depletion of ICOS-positive cells in vivo
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
AU2005267028A1 (en) 2004-07-22 2006-02-02 Genentech, Inc. Method of treating Sjogren's syndrome
JP4997108B2 (ja) 2005-07-22 2012-08-08 協和発酵キリン株式会社 遺伝子組換え抗体組成物
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (fr) * 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
US9585957B2 (en) 2007-09-07 2017-03-07 The Johns Hopkins University Adenosine receptor agonists and antagonists to modulate T cell responses
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
PT2970464T (pt) 2013-03-15 2020-08-05 Glaxosmithkline Ip Dev Ltd Proteínas de ligação anti-lag-3

Also Published As

Publication number Publication date
AR095432A1 (es) 2015-10-14
MA38498B1 (fr) 2018-11-30
UA118750C2 (uk) 2019-03-11
ES2808654T3 (es) 2021-03-01
US20190276535A1 (en) 2019-09-12
EP3712177A1 (fr) 2020-09-23
CA2902831C (fr) 2023-04-25
IL240838A0 (en) 2015-10-29
JP2018007668A (ja) 2018-01-18
DK2970464T3 (da) 2020-08-03
AU2014230741A1 (en) 2015-10-08
CN105209494A (zh) 2015-12-30
TWI658051B (zh) 2019-05-01
EA037554B1 (ru) 2021-04-13
PT2970464T (pt) 2020-08-05
SI2970464T1 (sl) 2020-08-31
EP2970464A1 (fr) 2016-01-20
JP6224739B2 (ja) 2017-11-01
MX2015012987A (es) 2015-12-15
US20230295295A1 (en) 2023-09-21
JP6833798B2 (ja) 2021-02-24
PL2970464T3 (pl) 2020-10-05
US20230242642A1 (en) 2023-08-03
UY35415A (es) 2014-10-31
PH12015502039A1 (en) 2016-01-18
HK1219966A1 (zh) 2017-04-21
SMT202000392T1 (it) 2020-09-10
PE20151530A1 (es) 2015-11-06
US10280221B2 (en) 2019-05-07
WO2014140180A1 (fr) 2014-09-18
US20160017037A1 (en) 2016-01-21
ME03796B (fr) 2021-04-20
CR20150492A (es) 2015-11-20
US20140286935A1 (en) 2014-09-25
RS60538B1 (sr) 2020-08-31
KR20150128879A (ko) 2015-11-18
IL240838B (en) 2022-09-01
AU2014230741B2 (en) 2017-04-13
NZ711355A (en) 2020-06-26
JP2019068826A (ja) 2019-05-09
TW201525000A (zh) 2015-07-01
CN105209494B (zh) 2019-04-09
EP2970464B1 (fr) 2020-05-06
HUE049957T2 (hu) 2020-11-30
PH12015502039B1 (en) 2019-09-25
HRP20201113T1 (hr) 2020-10-30
DOP2015000243A (es) 2015-12-31
EA201591467A1 (ru) 2016-04-29
CY1123220T1 (el) 2021-10-29
LT2970464T (lt) 2020-08-25
MX351349B (es) 2017-10-11
US10344088B2 (en) 2019-07-09
CA2902831A1 (fr) 2014-09-18
KR101763352B1 (ko) 2017-07-31
BR112015022593A2 (pt) 2017-10-24
US20190382482A1 (en) 2019-12-19
CL2015002517A1 (es) 2016-07-08
JP2016516681A (ja) 2016-06-09
SG11201506807RA (en) 2015-09-29

Similar Documents

Publication Publication Date Title
MA38498B1 (fr) Protéines de liaison anti-lag-3
SA522431756B1 (ar) Tigit أجسام مضادة لـ
MA40801B2 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
EA201890790A1 (ru) Связывающие pd-1 белки и способы их применения
EA201791754A1 (ru) АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
CU20120095A7 (es) Antagonistas de pcsk9
MA38500A1 (fr) Systèmes et procédés pour analyser une nourriture pour animal
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
EA201892412A1 (ru) Антитела, распознающие тау
EA202092420A1 (ru) Антитело против pd-l1 и его применение
EA201991876A1 (ru) Антитела против фактора d и их применения
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
PH12021553121A1 (en) Novel cthrc1-specific antibody and use thereof
EA202092265A1 (ru) Антитела против cd137 для комбинации с антителами против pd-l1
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
EA202090617A1 (ru) Варианты антител
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
EA202090727A1 (ru) Варианты антител
EA202193238A1 (ru) Аффинные агенты к аав9
EA201992598A1 (ru) Антитела, распознающие тау